AZD-8055
AZD-8055 is an ATP-competitive mTORC1/2 inhibitor that exhibits immunosuppressive and anticancer chemotherapeutic activities. AZD-8055 promotes antibody class switching in B cells at low doses and decreases B cell proliferation and differentiation at high doses. In vivo, this compound suppresses CC4+ and CD8+ T cell proliferation, increasing survival among MHC-mismatched heart transplant recipients. In vitro, AZD-8055 decreases viability of brain tumor cells; in vivo, it inhibits tumor growth.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18842797
| Cas No. |
1009298-09-2 |
|---|---|
| Purity |
≥98% |
| Formula |
C25H31N5O4 |
| Formula Wt. |
465.55 |
| Synonym |
AZD-8055 |
| Appearance |
Yellow powder |
Limon JJ, So L, Jellbauer S, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5076-85. PMID: 25385646.
Luchman HA, Stechishin OD, Nguyen SA, et al. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014 Nov 15;20(22):5756-67. PMID: 25316808.
Rosborough BR, Raïch-Regué D, Liu Q, et al. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014 Sep;14(9):2173-80. PMID: 25307040.
